Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis
This study constitutes a case-control investigation employing a retrospective approach. Plasma samples from individuals with esophageal cancer, benign esophageal diseases, gastric cancer, benign gastric diseases, and a healthy control group were systematically collected. Advanced Data-Independent Acquisition (DIA) proteomics and single-vesicle membrane protein detection techniques were employed to quantify protein content within exosomes. Specific protein biomarkers indicative of early-stage upper gastrointestinal tumors were identified. External validation of these protein markers was conducted using Parallel Reaction Monitoring (PRM) technology on an independent validation cohort. The objective is to establish protein marker predictions for early diagnosis of upper gastrointestinal tumors and prognostication of therapeutic efficacy.
- EligibilityCriteria: Inclusion Criteria:  Confirmed diagnosis of upper gastrointestinal cancers or benign upper gastrointestinal diseases through gastroscopy and pathological examination. Collection of plasma samples prior to surgical treatment. Availability of complete clinical data.  Exclusion Criteria:  Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. Coexistence of other systemic tumors. Absence of plasma sample collection before surgical treatment. Incomplete clinical data. Pregnancy status - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: The study population included a range of subjects with upper gastrointestinal cancers and diseases, including patients with malignant and benign upper gastrointestinal diseases and healthy controls, who were admitted to the main study center and other collaborating sub-center hospitals. - SamplingMethod: Non-Probability Sample